Clinical Trial Update: PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing prasugrel and clopidogrel in acute coronary syndrome patients with CYP2C19 variants; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndromes

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: Dong-A University | Conditions: Acute Coronary Syndromes | Phase 3 | Status: COMPLETED